The effects of taurolidine alone and in combination with doxorubicin or carboplatin in canine osteosarcoma in vitro

BMC Veterinary Research

Volumn 9, Issue , 2013, Pages

  Marley, Kevin ^a   Helfand, Stuart C ^a   Edris, Wade A ^a,b   Mata, John E ^a   Gitelman, Alix I ^a   Medlock, Jan ^a   Séguin, Bernard ^a,c  

^a OREGON STATE UNIVERSITY   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^c Veterinary Dentistry and Oral Surgery   (United States)

Author keywords

Apoptosis; Carboplatin; Doxorubicin; In vitro; Osteosarcoma; Taurolidine

Indexed keywords

CANIS FAMILIARIS;

ANTINEOPLASTIC AGENT; CARBOPLATIN; DOXORUBICIN; DRUG DERIVATIVE; TAURINE; TAUROLIDINE; THIADIAZINE DERIVATIVE;

ANIMAL; ANIMAL DISEASE; ARTICLE; BONE TUMOR; DOG; DOG DISEASE; DOSE RESPONSE; DRUG COMBINATION; HUMAN; IN VITRO STUDY; OSTEOSARCOMA; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CARBOPLATIN; CELL LINE, TUMOR; DOG DISEASES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG THERAPY, COMBINATION; HUMANS; OSTEOSARCOMA; TAURINE; THIADIAZINES;

MLCS; MLOWN;

EID: 84872328380     PISSN: None     EISSN: 17466148     Source Type: Journal    
DOI: 10.1186/1746-6148-9-15     Document Type: Article

References (30)

1. Royals SR, Farese JP, Milner RJ, Lee-Ambrose L, van Gilder J. Investigation of the effects of deracoxib and piroxicam on the in vitro viability of osteosarcoma cells from dogs. Am J Vet Res 2005, 66(11):1961-1967. 10.2460/ajvr.2005.66.1961, 16334957.
2. Imhof L, Goldinger SM, Baumann K, Schad K, French LE, Rothlisberger P, Dummer R. The antibacterial substance, taurolidine in the second/third-line treatment of very advanced stage IV melanoma including brain metastases: results of a phase 2, open-label study. Melanoma Res 2011, 21(1):80-83.
3. Chromik AM, Daigeler A, Bulut D, Flier A, May C, Harati K, Roschinsky J, Sulberg D, Ritter PR, Mittelkotter U, et al. Comparative analysis of cell death induction by Taurolidine in different malignant human cancer cell lines. J Exp Clin Cancer Res 2010, 29:21. 10.1186/1756-9966-29-21, 2846881, 20205945.
4. Braumann C, Jacobi CA, Rogalla S, Menenakos C, Fuehrer K, Trefzer U, Hofmann M. The tumor suppressive reagent taurolidine inhibits growth of malignant melanoma-a mouse model. J Surg Res 2007, 143(2):372-378. 10.1016/j.jss.2007.01.041, 17612567.
5. Braumann C, Ordemann J, Kilian M, Wenger FA, Jacobi CA. Local and systemic chemotherapy with taurolidine and taurolidine/heparin in colon cancer-bearing rats undergoing laparotomy. Clin Exp Metastasis 2003, 20(5):387-394. 10.1023/A:1025402919341, 14524527.
6. Jacobi CA, Menenakos C, Braumann C. Taurolidine-a new drug with anti-tumor and anti-angiogenic effects. Anticancer Drugs 2005, 16(9):917-921. 10.1097/01.cad.0000176502.40810.b0, 16162968.
7. Gong L, Greenberg HE, Perhach JL, Waldman SA, Kraft WK. The pharmacokinetics of taurolidine metabolites in healthy volunteers. J Clin Pharmacol 2007, 47(6):697-703. 10.1177/0091270007299929, 17395893.
8. Petrovic L, Schlegel KA, Ries J, Park J, Diebel E, Schultze-Mosgau S, Wiltfang J. [In vitro effect of taurolidine on squamous cell carcinoma in the oral cavity]. Mund Kiefer Gesichtschir 2003, 7(2):102-107. 10.1007/s10006-003-0452-5, 12664255.
9. Sun BS, Wang JH, Liu LL, Gong SL, Redmond HP. Taurolidine induces apoptosis of murine melanoma cells in vitro and in vivo by modulation of the Bcl-2 family proteins. J Surg Oncol 2007, 96(3):241-248. 10.1002/jso.20827, 17469118.
10. Walters DK, Muff R, Langsam B, Gruber P, Born W, Fuchs B. Taurolidine: a novel anti-neoplastic agent induces apoptosis of osteosarcoma cell lines. Invest New Drugs 2007, 25(4):305-312. 10.1007/s10637-007-9052-9, 17458504.
11. McCourt M, Wang JH, Sookhai S, Redmond HP. Taurolidine inhibits tumor cell growth in vitro and in vivo. Ann Surg Oncol 2000, 7(9):685-691. 10.1007/s10434-000-0685-6, 11034247.
12. Nici L, Monfils B, Calabresi P. The effects of taurolidine, a novel antineoplastic agent, on human malignant mesothelioma. Clin Cancer Res 2004, 10(22):7655-7661. 10.1158/1078-0432.CCR-0196-03, 15569998.
13. Kruse JP, Gu W. Modes of p53 regulation. Cell 2009, 137(4):609-622. 10.1016/j.cell.2009.04.050, 19450511.
14. Mohler T, Willhauk-Fleckenstrin M, Shwartz-Albiez R, Merling A, Mohler H. Inhibition of endothelial cell adhesion and in vitro angiogenesis by taurolidine. Cancer Therapy 2008, 6:623-628.
15. Stendel R, Biefer HR, Dekany GM, Kubota H, Munz C, Wang S, Mohler H, Yonekawa Y, Frei K. The antibacterial substance taurolidine exhibits anti-neoplastic action based on a mixed type of programmed cell death. Autophagy 2009, 5(2):194-210. 10.4161/auto.5.2.7404, 19066471.
16. Braumann C, Winkler G, Rogalla P, Menenakos C, Jacobi CA. Prevention of disease progression in a patient with a gastric cancer-re-recurrence. Outcome after intravenous treatment with the novel antineoplastic agent taurolidine. Report of a case. World J Surg Oncol 2006, 4:34. 10.1186/1477-7819-4-34, 1544327, 16796759.
17. Stendel R, Picht T, Schilling A, Heidenreich J, Loddenkemper C, Janisch W, Brock M. Treatment of glioblastoma with intravenous taurolidine. First clinical experience. Anticancer Res 2004, 24(2C):1143-1147.
18. Seguin B, Zwerdling T, McCallan JL, DeCock HE, Dewe LL, Naydan DK, Young AE, Bannasch DL, Foreman O, Kent MS. Development of a new canine osteosarcoma cell line. Vet Comp Oncol 2006, 4(4):232-240. 10.1111/j.1476-5829.2006.00112.x, 19754807.
19. Shoieb AM, Hahn KA, Barnhill MA. An in vivo/in vitro experimental model system for the study of human osteosarcoma: canine osteosarcoma cells (COS31) which retain osteoblastic and metastatic properties in nude mice. In Vivo 1998, 12(5):463-472.
20. Barroga EF, Kadosawa T, Okumura M, Fujinaga T. Establishment and characterization of the growth and pulmonary metastasis of a highly lung metastasizing cell line from canine osteosarcoma in nude mice. J Vet Med Sci 1999, 61(4):361-367. 10.1292/jvms.61.361, 10342286.
21. Hershey AE, Dubielzig RR, Padilla ML, Helfand SC. Aberrant p53 expression in feline vaccine-associated sarcomas and correlation with prognosis. Vet Pathol 2005, 42(6):805-811. 10.1354/vp.42-6-805, 16301577.
22. Ozaki T, Nakagawara A. p53: the attractive tumor suppressor in the cancer research field. J Biomed Biotechnol 2011, 603925.
23. Lukic A, Vasilijic S, Majstorovic I, Vucevic D, Mojsilovic S, Gazivoda D, Danilovic V, Petrovic R, Colic M. Characterization of antigen-presenting cells in human apical periodontitis lesions by flow cytometry and immunocytochemistry. Int Endod J 2006, 39(8):626-636. 10.1111/j.1365-2591.2006.01125.x, 16872457.
24. Diaz LK, Gupta R, Kidwai N, Sneige N, Wiley EL. The use of TMA for interlaboratory validation of FISH testing for detection of HER2 gene amplification in breast cancer. J Histochem Cytochem 2004, 52(4):501-507. 10.1177/002215540405200408, 15034001.
25. Aapro MS, Alberts DS, Salmon SE. Interactions of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assay. Cancer Chemother Pharmacol 1983, 10(3):161-166.
26. Wolfesberger B, Hoelzl C, Walter I, Reider GA, Fertl G, Thalhammer JG, Skalicky M, Egerbacher M. In vitro effects of meloxicam with or without doxorubicin on canine osteosarcoma cells. J Vet Pharmacol Ther 2006, 29(1):15-23. 10.1111/j.1365-2885.2006.00704.x, 16420297.
27. Liu JY, Liu Z, Wang DM, Li MM, Wang SX, Wang R, Chen JP, Wang YF, Yang DP. Induction of apoptosis in K562 cells by dicyclohexylammonium salt of hyperforin through a mitochondrial-related pathway. Chem Biol Interact 2011, 190(2-3):91-101.
28. Suzuki K, Matsubara H. Recent advances in p53 research and cancer treatment. J Biomed Biotechnol 2011, 978312.
29. Stendel R, Scheurer L, Schlatterer K, Stalder U, Pfirrmann RW, Fiss I, Mohler H, Bigler L. Pharmacokinetics of taurolidine following repeated intravenous infusions measured by HPLC-ESI-MS/MS of the derivatives taurultame and taurinamide in glioblastoma patients. Clin Pharmacokinet 2007, 46(6):513-524. 10.2165/00003088-200746060-00005, 17518510.
30. Liptak JMDW, Ehrhart N, Withrow SJ, Seguin B, Walsh PJ, Kuntz CA. Canine appendicular osteosarcoma: curative-intent treatment. Compend Contin Educ Gen Dent 2004, 26:186-196.